For patients who do not have chronic kidney disease or cardiovascular disease but have at least three risk factors from Table 1 , SGLT-2 inhibitors decrease mortality with an NNT of 100 (95% CI, 67 to 167) over five years
Moreover, d-allulose (1 g kg 1 ) failed to alter blood glucose levels in Glp1r KO mice (Fig
Consult en mai 2020. Thakker D, Raval A, Patel I, Walia R
Clinical data suggests musculoskeletal discomfort occurs in a minority of users and may be related to rapid weight loss, metabolic shifts, or individual genetic predispositions rather than the medication itself
Indrukwekkend gewichtsverlies Een van de meest opvallende voordelen van Mounjaro is het effect op gewichtsverlies
This study showed that GLP-1 receptor agonist use was associated with markedly diminished risks of cirrhosis (aHR: 0.72, 95%CI: 0.66-0.79) and HCC (aHR: 0.65, 95%CI: 0.56-0.76) compared to non-use throughout a mean observation period of 4.8 years, with benefits observed across different baseline liver disease stages [57]
